BioView Gets FDA OK for Duet System for ALK Rearrangements | GenomeWeb

NEW YORK (GenomeWeb) – BioView announced on Wednesday that the US Food and Drug Administration has cleared for marketing the firm's Duet System to detect rearrangements involving the ALK gene in non-small cell lung cancer samples.

Specifically, the system has been cleared for the qualitative detection of ALK rearrangements via fluorescence in situ hybridization in formalin-fixed paraffin-embedded NSCLC tissue specimens that are probed with the Abbott Vysis ALK Break Apart FISH Probe Kit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.